Literature DB >> 3284989

Heart transplantation for cardiac amyloidosis: successful one-year outcome despite recurrence of the disease.

R Conner1, J D Hosenpud, D J Norman, G A Pantely, A Cobanoglu, A Starr.   

Abstract

Systemic amyloidosis has been considered a theoretical contraindication for heart transplantation because of the concern that amyloidosis is a systemic disease that could potentially recur in the allograft. To date, no patients have been reported to have undergone heart transplantation. One year ago a patient with amyloidosis had a transplantation at the Oregon Health Sciences University, Portland. Results of kidney, rectal, and bone marrow biopsies were normal; however, endomyocardial and gingival biopsies showed positive results for amyloidosis. Recurrence of amyloidosis was detected by electron microscopy 14 weeks after transplantation; however, light microscopy has not shown any amyloidosis at 1 year. No other organ involvement has been documented. The patient is New York Heart Association functional class I, with normal resting hemodynamic parameters 1 year after transplantation. Amyloid heart disease does not necessarily portend a poor early outcome.

Entities:  

Mesh:

Year:  1988        PMID: 3284989

Source DB:  PubMed          Journal:  J Heart Transplant        ISSN: 0887-2570


  6 in total

1.  Long term results of heart transplantation in patients with amyloid heart disease.

Authors:  S W Dubrey; M M Burke; A Khaghani; P N Hawkins; M H Yacoub; N R Banner
Journal:  Heart       Date:  2001-02       Impact factor: 5.994

Review 2.  Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs.

Authors:  Adam Castaño; Brian M Drachman; Daniel Judge; Mathew S Maurer
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

3.  Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure.

Authors:  Bimalangshu R Dey; Stephen S Chung; Thomas R Spitzer; Hui Zheng; Thomas E Macgillivray; David C Seldin; Steven McAfee; Karen Ballen; Eyal Attar; Thomas Wang; Jordan Shin; Christopher Newton-Cheh; Stephanie Moore; Vaishali Sanchorawala; Martha Skinner; Joren C Madsen; Marc J Semigran
Journal:  Transplantation       Date:  2010-10-27       Impact factor: 4.939

Review 4.  Emerging Advances in the Management of Cardiac Amyloidosis.

Authors:  Michael N Vranian; Brett W Sperry; Jason Valent; Mazen Hanna
Journal:  Curr Cardiol Rep       Date:  2015-11       Impact factor: 2.931

Review 5.  Heart transplantation in cardiac amyloidosis.

Authors:  Matthew Sousa; Gregory Monohan; Navin Rajagopalan; Alla Grigorian; Maya Guglin
Journal:  Heart Fail Rev       Date:  2017-05       Impact factor: 4.214

6.  Morphologic features of the recipient heart in patients having cardiac transplantation and analysis of the congruence or incongruence between the clinical and morphologic diagnoses.

Authors:  William C Roberts; Carey Camille Roberts; Jong Mi Ko; Giovanni Filardo; John Edward Capehart; Shelley Anne Hall
Journal:  Medicine (Baltimore)       Date:  2014-07       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.